Comparison of PathVysion and INFORM Fluorescence In Situ Hybridization Kits for Assessment of HER-2/neu Status in Breast Carcinoma

被引：0

作者：

Sanjay Kakar

Nick Puangsuvan

Jane M. Stevens

Romualda Serenas

George Mangan

Shalini Sahai

Michael L. Mihalov

机构：

[1] University of Illinois at Chicago,Department of Pathology

来源：

Molecular Diagnosis | 2000年 / 5卷 / 3期

关键词：

PathVysion; INFORM; prognosis; immunohistochemistry;

D O I：

10.1007/BF03262076

中图分类号：

学科分类号：

摘要：

Background: Fluorescence in situ hybridization is advocated for precise assessment of HER-2/neu status in breast carcinoma; however, few objective data compare available kits for clinical laboratories contemplating development of the test.

引用

页码：193 / 197

页数：4

共 50 条

[31] Is initial screening by fluorescence in situ hybridization necessary for accurate determination of HER-2/neu status in breast cancer?
Yaziji, H
Wirtala, J
Davie, P
Gown, AM
BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 242 - 242
[32] Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis
Lehr, HA
Jacobs, TW
Yaziji, H
Schnitt, SJ
Gown, AM
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2001, 115 (06) : 814 - 822
[33] Effects of fixative and fixation protocols on assessment of Her-2/neu oncogene amplification status by fluorescence in situ hybridization
Willmore-Payne, Carlynn
Metzger, Ken
Layfield, Lester J.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2007, 15 (01) : 84 - 87
[34] Comparison of in situ hybridization methods for the assessment of HER-2/neu gene amplification status in breast cancer using a tissue microarray
Malicka-Durczak, Anna
Korski, Konstanty
Ibbs, Matthew
REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2012, 17 (01) : 44 - 49
[35] Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer:: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility
Gong, Y
Gilcrease, M
Sneige, N
MODERN PATHOLOGY, 2005, 18 (08) : 1015 - 1021
[36] Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer
Rosenthal, SI
Depowski, PL
Sheehan, CE
Ross, JS
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2002, 10 (01): : 40 - 46
[37] Comparison of HER-2/neu status determined by fluorescence in situ hybridization (FISH) in the BCIRG central laboratories with HER-2/neu status determined by immunohistochemistry or FISH in outside laboratories.
Press, MF
Sauter, G
Bernstein, L
Zhou, J
Li, B
Mirlacher, M
Villalobos, I
Guzman, R
Riva, A
Nabholtz, JM
Slamon, DJ
BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S69 - S69
[38] Comparison of chromogenic in situ hybridisation with fluorescence in situ hybridisation and immunohistochemistry for the assessment of Her-2/neu oncogene in archival material of breast carcinoma
Pothos, Alexios
Plastira, Konstantina
Plastiras, Aris
Vlachodimitropoulos, Dimitrios
Goutas, Nikolaos
Angelopoulou, Roxani
ACTA HISTOCHEMICA ET CYTOCHEMICA, 2008, 41 (03) : 59 - 64
[39] Assessment of Her-2/neu gene amplification status in breast carcinoma with equivocal 2+ Her-2/neu immunostaining
Mostafa, Naglaa A. E.
Eissa, Saad S.
Belal, Dalia M.
Shoman, Soheir H.
JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2011, 23 (01) : 41 - 46
[40] Suggestions for HER-2/neu testing in breast carcinoma, based on a comparison of immunohistochemistry and fluorescence in situ hybridisation
Field, AS
Chamberlain, NL
Tran, D
Morey, AL
PATHOLOGY, 2001, 33 (03) : 278 - 282

← 1 2 3 4 5 →